Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.54 |
| ▸ | MAOB | P27338 | 6/20 | 0.54 |
| ▸ | AR | P10275 | 10/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL524184 | 0.81 | AR (0.51) | ARMEN1KMT2AALDH1A1GAA | |
| SCHEMBL8568346 | 0.74 | MAOB (0.65) | MAOAMAOBMEN1KMT2AMAPT | |
| SCHEMBL2707655 | 0.74 | CA1 (0.47) | ALDH1A1MAPT | |
| SCHEMBL920849 | 0.73 | MAOA (0.58) | MAOAMAOBAR | |
| SCHEMBL3394075 | 0.73 | MAOB (0.81) | MAOAMAOBALDH1A1 | |
| SCHEMBL8863839 | 0.72 | GFER (0.48) | KMT2AALDH1A1GAAMAPTDYRK1A | |
| SCHEMBL5788515 | 0.72 | MAOB (1.00) | MAOAMAOBMEN1KMT2AALDH1A1 | |
| SCHEMBL2731932 | 0.71 | AR (0.66) | MAOAMAOBARMEN1KMT2A | |
| SCHEMBL11481188 | 0.71 | AR (0.50) | ARMEN1KMT2ADYRK1ASLC6A4 | |
| SCHEMBL524339 | 0.71 | AR (0.58) | ARMEN1KMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435462-A1 | NOVEL GLUCOCORTICOID RECEPTOR AGONISTS | Pfizer Limited (GB) | 2012-04-04 | — | — | EP | disclosed |
| WO-2010136940-A1 | NOVEL GLUCOCORTICOID RECEPTOR AGONISTS | PFIZER LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136940-A1 | NOVEL GLUCOCORTICOID RECEPTOR AGONISTS | PFIZER LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | GLOSSOP PAUL ALAN | 2010-12-02 | — | — | US | disclosed |
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | GLOSSOP PAUL ALAN | 2010-12-02 | — | — | US | disclosed |
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | GLOSSOP PAUL ALAN | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | NR3C1, NR3C2, MC2R | MAOA 2370/4885MAOB 3226/4885AR 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.